File Download
 
Links for fulltext
(May Require Subscription)
 
Supplementary

Article: Profiles of HBV DNA in a large population of Chinese patients with chronic hepatitis B: Implications for antiviral therapy
  • Basic View
  • Metadata View
  • XML View
TitleProfiles of HBV DNA in a large population of Chinese patients with chronic hepatitis B: Implications for antiviral therapy
 
AuthorsFung, J1
Seto, WK1
Lai, CL1
Yuen, J1
Wong, DKH1
Yuen, MF1
 
KeywordsAntiviral therapy
Chronic hepatitis B
HBV DNA
Treatment guidelines
Viral load
 
Issue Date2011
 
PublisherElsevier BV. The Journal's web site is located at http://www.elsevier.com/locate/jhep
 
CitationJournal Of Hepatology, 2011, v. 54 n. 2, p. 195-200 [How to Cite?]
DOI: http://dx.doi.org/10.1016/j.jhep.2010.06.031
 
AbstractBackground & Aims: We determined the virological profile in Chinese chronic hepatitis B (CHB) subjects and its implications regarding current treatment guidelines. Methods: A total of 1400 treatment-naïve CHB patients had their HBV DNA levels determined using the Cobas Taqman assay. Patient demographics, HBeAg status, and liver biochemistry were also recorded. Results: The subjects were predominantly male (62%), had a median age of 45 years, and 301 (22%) were HBeAg-positive. In subjects aged ≤25, 26-35, 36-45, 46-55, and >55 years, there was a decreasing trend of HBV DNA levels of 9.9, 9.3, 8.2, 7.4, and 7.3 log copies/ml, respectively (p <0.001), in HBeAg-positive subjects, while the pattern was reversed with HBV DNA levels of 3.7, 4.4, 4.7, 4.9, and 5.2 log copies/ml, respectively, in HBeAg-negative subjects (p <0.001). In HBeAg-negative subjects, the proportion of patients with elevated ALT compared to those with normal ALT was significantly higher in older age groups (p <0.001). In our study population, by applying the AASLD, EASL, and APASL guidelines, 64%, 99%, and 64% would be eligible for antiviral therapy, respectively, in HBeAg-positive patients (with elevated ALT), and 38%, 72%, and 43%, respectively, in HBeAg-negative patients (with elevated ALT). Up to 54% of patients over the age of 40 years would be recommended for liver biopsy to determine further eligibility for treatment. Conclusions: For HBeAg-negative CHB, more patients had elevated ALT and a higher viral load with increasing age. Close monitoring is recommended in this group so that treatment may be considered. By applying the current treatment guidelines, a wide discrepancy can be observed in the proportion of patients eligible for treatment in the absence of histological data. © 2010 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
 
ISSN0168-8278
2012 Impact Factor: 9.858
2012 SCImago Journal Rankings: 2.797
 
DOIhttp://dx.doi.org/10.1016/j.jhep.2010.06.031
 
ISI Accession Number IDWOS:000287070400004
Funding AgencyGrant Number
Bristol-Myer-Squibb
Funding Information:

This study has been generously supported by an unrestricted grant from Bristol-Myer-Squibb.

 
ReferencesReferences in Scopus
 
DC FieldValue
dc.contributor.authorFung, J
 
dc.contributor.authorSeto, WK
 
dc.contributor.authorLai, CL
 
dc.contributor.authorYuen, J
 
dc.contributor.authorWong, DKH
 
dc.contributor.authorYuen, MF
 
dc.date.accessioned2011-09-23T05:50:30Z
 
dc.date.available2011-09-23T05:50:30Z
 
dc.date.issued2011
 
dc.description.abstractBackground & Aims: We determined the virological profile in Chinese chronic hepatitis B (CHB) subjects and its implications regarding current treatment guidelines. Methods: A total of 1400 treatment-naïve CHB patients had their HBV DNA levels determined using the Cobas Taqman assay. Patient demographics, HBeAg status, and liver biochemistry were also recorded. Results: The subjects were predominantly male (62%), had a median age of 45 years, and 301 (22%) were HBeAg-positive. In subjects aged ≤25, 26-35, 36-45, 46-55, and >55 years, there was a decreasing trend of HBV DNA levels of 9.9, 9.3, 8.2, 7.4, and 7.3 log copies/ml, respectively (p <0.001), in HBeAg-positive subjects, while the pattern was reversed with HBV DNA levels of 3.7, 4.4, 4.7, 4.9, and 5.2 log copies/ml, respectively, in HBeAg-negative subjects (p <0.001). In HBeAg-negative subjects, the proportion of patients with elevated ALT compared to those with normal ALT was significantly higher in older age groups (p <0.001). In our study population, by applying the AASLD, EASL, and APASL guidelines, 64%, 99%, and 64% would be eligible for antiviral therapy, respectively, in HBeAg-positive patients (with elevated ALT), and 38%, 72%, and 43%, respectively, in HBeAg-negative patients (with elevated ALT). Up to 54% of patients over the age of 40 years would be recommended for liver biopsy to determine further eligibility for treatment. Conclusions: For HBeAg-negative CHB, more patients had elevated ALT and a higher viral load with increasing age. Close monitoring is recommended in this group so that treatment may be considered. By applying the current treatment guidelines, a wide discrepancy can be observed in the proportion of patients eligible for treatment in the absence of histological data. © 2010 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
 
dc.description.natureLink_to_subscribed_fulltext
 
dc.identifier.citationJournal Of Hepatology, 2011, v. 54 n. 2, p. 195-200 [How to Cite?]
DOI: http://dx.doi.org/10.1016/j.jhep.2010.06.031
 
dc.identifier.citeulike7836287
 
dc.identifier.doihttp://dx.doi.org/10.1016/j.jhep.2010.06.031
 
dc.identifier.epage200
 
dc.identifier.hkuros195206
 
dc.identifier.hkuros189852
 
dc.identifier.hkuros213684
 
dc.identifier.hkuros213684
 
dc.identifier.isiWOS:000287070400004
Funding AgencyGrant Number
Bristol-Myer-Squibb
Funding Information:

This study has been generously supported by an unrestricted grant from Bristol-Myer-Squibb.

 
dc.identifier.issn0168-8278
2012 Impact Factor: 9.858
2012 SCImago Journal Rankings: 2.797
 
dc.identifier.issue2
 
dc.identifier.pmid21056499
 
dc.identifier.scopuseid_2-s2.0-78751578866
 
dc.identifier.spage195
 
dc.identifier.urihttp://hdl.handle.net/10722/139478
 
dc.identifier.volume54
 
dc.languageeng
 
dc.publisherElsevier BV. The Journal's web site is located at http://www.elsevier.com/locate/jhep
 
dc.publisher.placeNetherlands
 
dc.relation.ispartofJournal of Hepatology
 
dc.relation.referencesReferences in Scopus
 
dc.subject.meshAlanine Transaminase - blood
 
dc.subject.meshDNA, Viral - analysis
 
dc.subject.meshHepatitis B virus - genetics - isolation and purification
 
dc.subject.meshHepatitis B, Chronic - drug therapy - virology
 
dc.subject.meshViral Load
 
dc.subjectAntiviral therapy
 
dc.subjectChronic hepatitis B
 
dc.subjectHBV DNA
 
dc.subjectTreatment guidelines
 
dc.subjectViral load
 
dc.titleProfiles of HBV DNA in a large population of Chinese patients with chronic hepatitis B: Implications for antiviral therapy
 
dc.typeArticle
 
<?xml encoding="utf-8" version="1.0"?>
<item><contributor.author>Fung, J</contributor.author>
<contributor.author>Seto, WK</contributor.author>
<contributor.author>Lai, CL</contributor.author>
<contributor.author>Yuen, J</contributor.author>
<contributor.author>Wong, DKH</contributor.author>
<contributor.author>Yuen, MF</contributor.author>
<date.accessioned>2011-09-23T05:50:30Z</date.accessioned>
<date.available>2011-09-23T05:50:30Z</date.available>
<date.issued>2011</date.issued>
<identifier.citation>Journal Of Hepatology, 2011, v. 54 n. 2, p. 195-200</identifier.citation>
<identifier.issn>0168-8278</identifier.issn>
<identifier.uri>http://hdl.handle.net/10722/139478</identifier.uri>
<description.abstract>Background &amp; Aims: We determined the virological profile in Chinese chronic hepatitis B (CHB) subjects and its implications regarding current treatment guidelines. Methods: A total of 1400 treatment-na&#239;ve CHB patients had their HBV DNA levels determined using the Cobas Taqman assay. Patient demographics, HBeAg status, and liver biochemistry were also recorded. Results: The subjects were predominantly male (62%), had a median age of 45 years, and 301 (22%) were HBeAg-positive. In subjects aged &#8804;25, 26-35, 36-45, 46-55, and &gt;55 years, there was a decreasing trend of HBV DNA levels of 9.9, 9.3, 8.2, 7.4, and 7.3 log copies/ml, respectively (p &lt;0.001), in HBeAg-positive subjects, while the pattern was reversed with HBV DNA levels of 3.7, 4.4, 4.7, 4.9, and 5.2 log copies/ml, respectively, in HBeAg-negative subjects (p &lt;0.001). In HBeAg-negative subjects, the proportion of patients with elevated ALT compared to those with normal ALT was significantly higher in older age groups (p &lt;0.001). In our study population, by applying the AASLD, EASL, and APASL guidelines, 64%, 99%, and 64% would be eligible for antiviral therapy, respectively, in HBeAg-positive patients (with elevated ALT), and 38%, 72%, and 43%, respectively, in HBeAg-negative patients (with elevated ALT). Up to 54% of patients over the age of 40 years would be recommended for liver biopsy to determine further eligibility for treatment. Conclusions: For HBeAg-negative CHB, more patients had elevated ALT and a higher viral load with increasing age. Close monitoring is recommended in this group so that treatment may be considered. By applying the current treatment guidelines, a wide discrepancy can be observed in the proportion of patients eligible for treatment in the absence of histological data. &#169; 2010 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.</description.abstract>
<language>eng</language>
<publisher>Elsevier BV. The Journal&apos;s web site is located at http://www.elsevier.com/locate/jhep</publisher>
<relation.ispartof>Journal of Hepatology</relation.ispartof>
<subject>Antiviral therapy</subject>
<subject>Chronic hepatitis B</subject>
<subject>HBV DNA</subject>
<subject>Treatment guidelines</subject>
<subject>Viral load</subject>
<subject.mesh>Alanine Transaminase - blood</subject.mesh>
<subject.mesh>DNA, Viral - analysis</subject.mesh>
<subject.mesh>Hepatitis B virus - genetics - isolation and purification</subject.mesh>
<subject.mesh>Hepatitis B, Chronic - drug therapy - virology</subject.mesh>
<subject.mesh>Viral Load</subject.mesh>
<title>Profiles of HBV DNA in a large population of Chinese patients with chronic hepatitis B: Implications for antiviral therapy</title>
<type>Article</type>
<description.nature>Link_to_subscribed_fulltext</description.nature>
<identifier.doi>10.1016/j.jhep.2010.06.031</identifier.doi>
<identifier.pmid>21056499</identifier.pmid>
<identifier.scopus>eid_2-s2.0-78751578866</identifier.scopus>
<identifier.hkuros>195206</identifier.hkuros>
<identifier.hkuros>189852</identifier.hkuros>
<identifier.hkuros>213684</identifier.hkuros>
<identifier.hkuros>213684</identifier.hkuros>
<relation.references>http://www.scopus.com/mlt/select.url?eid=2-s2.0-78751578866&amp;selection=ref&amp;src=s&amp;origin=recordpage</relation.references>
<identifier.volume>54</identifier.volume>
<identifier.issue>2</identifier.issue>
<identifier.spage>195</identifier.spage>
<identifier.epage>200</identifier.epage>
<identifier.isi>WOS:000287070400004</identifier.isi>
<publisher.place>Netherlands</publisher.place>
<identifier.citeulike>7836287</identifier.citeulike>
</item>
Author Affiliations
  1. The University of Hong Kong